PBYI

Rating neutralTentativeAI MemoPost-earnings T+3

Puma Biotechnology

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 beat and raised full-year outlook • 2026-08-08

Base target: $9 / p=50% prob

Biggest risk

Cash from operations fell to $1.6M from $14.1M year over year, first-half net income declined to $4.4M from $8.8M, cash and marketable securities fell to $93.9M, and R&D increased materially with higher alisertib activity. Royalty guidance was reduced and pipeline outcomes remain uncertain.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The Q2 print exceeded the packet's limited consensus expectations, NERLYNX product revenue grew year over year, FY2026 revenue and net-income guidance increased, and the company remains debt-free. Alisertib milestones provide additional option value.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

p=50%

Bull target

$11

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings valuation digestion
ALISCA-Lung2 enrollment initiation
Alisertib enrollment expansion and Breast1 data

BearKey bullets

Higher alisertib R&D spending increases execution and funding sensitivity before clinical validation.
NERLYNX remains the principal commercial revenue driver, while royalty revenue and royalty guidance declined.
Operating cash flow weakened sharply despite the quarterly profit, and cash declined from year-end.

WatchKey bullets

Q2 beat and raised full-year outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $9 (p=50%)

Target spread vs base: +26% / -31%

Scenario probabilities

Bull Target: $11 (p=25%)Base Target: $9 (p=50%)Bear Target: $6 (p=25%)

Commentary

News tone is mildly positive after the Q2 beat, raised full-year guidance, and approximately 9.5% post-print price increase. Analyst revision and target-change evidence is unavailable, coverage is thin, and social coverage is absent; this supports monitoring rather than a high-conviction upgrade.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings valuation digestion
ALISCA-Lung2 enrollment initiation
Alisertib enrollment expansion and Breast1 data

Scenarios

Bull Target (Scenario probability)

$11 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-08
Q2 beat and raised full-year outlook
Q2 revenue was $56.5M and GAAP EPS was $0.16 versus packet consensus expectations of $53.17M and $0.10. Management raised FY2026 total-revenue guidance to $224–231M and net-income guidance to $17–20M, while lowering royalty guidance. The 8-K furnished the earnings release [#SEC-8K-2026-08-06] [#8-K-2026-08-06].
Prob 90.00% • Move 6.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Post-earnings valuation digestion
2026-08-31
The shares were quoted at $8.91, up approximately 9.5% from the prior close after the print. With sparse analyst coverage and a reported median target of $6.00, further upside may require continued delivery against raised guidance.
Prob 65% • Move -7% • Priced-in 75%

Long-term Catalysts

Months to a year

ALISCA-Lung2 enrollment initiation
2026-09-30
Management identified initiation of enrollment in ALISCA-Lung2, a Phase I/II alisertib plus paclitaxel trial in extensive-stage small-cell lung cancer, as a Q3 2026 milestone [#SEC-8K-2026-08-06].
Prob 55% • Move 15% • Priced-in 35%
Alisertib enrollment expansion and Breast1 data
2026-12-31
The company expects expansion of ALISCA-Breast1 and ALISCA-Lung1 enrollment in H2 2026 and updated ALISCA-Breast1 data in Q4 2026. These remain clinical execution milestones rather than validated efficacy catalysts [#SEC-8K-2026-08-06].
Prob 50% • Move 18% • Priced-in 30%

Risks

Higher alisertib R&D spending increases execution and funding sensitivity before clinical validation.
NERLYNX remains the principal commercial revenue driver, while royalty revenue and royalty guidance declined.
Operating cash flow weakened sharply despite the quarterly profit, and cash declined from year-end.
Recent open-market sales by the CEO and directors may weigh on sentiment, but do not provide operating evidence [#SEC-FORM4-2026-07-08] [#SEC-FORM4-2026-06-15].
The ALISCA programs remain event-driven and exposed to enrollment, efficacy, safety, and regulatory risk.

Peers

Symbol	Summary
CABA	Same-sector, similar-market-cap biotech comparator; the packet does not establish direct operating comparability with Puma.
EPRX	Same-sector, similar-market-cap comparator useful for small-cap biotech risk sentiment, but not a clean commercial-peer match.
PRTA	Same-sector, similar-market-cap biotech comparator; limited packet evidence supports using it only as a broad valuation and volatility reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

CABA

Same-sector, similar-market-cap biotech comparator; the packet does not establish direct operating comparability with Puma.

EPRX

Same-sector, similar-market-cap comparator useful for small-cap biotech risk sentiment, but not a clean commercial-peer match.

PRTA

Same-sector, similar-market-cap biotech comparator; limited packet evidence supports using it only as a broad valuation and volatility reference.